Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by cpacon Dec 27, 2019 11:30am

315 Views

Post# 30493929

RE:RE:RE:RE:RE:Is this the prelude to a buyout?

I have long thought that Pelareorep has the potential to be $1 billion plus in peak sales... as an adjuvant to the heavy hitters in immunoncology drugs it meaningfully improves outcomes... so what is a company with that kind of drug worth?? At least 1 billion in market cap I would say... with only 25 million shares out, that puts us close to $40... so I am with Canadafan for sure.

By the way, public service announcement to not ignore the warrants! They don't expire until June 2022... lots of time value left ... If ONC triples in price these year, they probably go up 10x from these levels. I hold both a whack of the shares and a whack of the warrants.

Cheers,
CPAC

Bullboard Posts

Canada Nickel unveils second of seven resources planned by mid-2025